Lantern Pharma Inc.'s LP-284 has been awarded orphan drug designation by the FDA for the treatment of mantle cell lymphoma (MCL). LP-284 is a novel small-molecule agent that preferentially damages DNA in cancer cells harboring mutations in DNA damage repair pathways.
PDX Pharmaceuticals Inc.'s ARAC-02 has been selected to enter the Nanotechnology Characterization Laboratory (NCL)'s Assay Cascade Characterization Program.
Abbvie Inc. and Immunome Inc. have announced a worldwide collaboration and option agreement for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's discovery engine.
Frontier Medicines Corp. has selected its first development candidate, FMC-376, an oral, covalent small-molecule inhibitor that selectively targets both active (GTP-bound) and inactive (GDP-bound) conformations of KRAS G12C.
Tencent Technology (Shenzhen) Co. Ltd. has disclosed pyrrolo[2,1-f][1,2,4]triazine derivatives acting as dual specificity protein kinase TTK inhibitors reported to be useful for the treatment of cancer.
Metacen Therapeutics Corp. has synthesized compounds able to capture methylglyoxal (MGO) reported to be useful for the treatment of aging, diabetes, hyperlipidemia, neurodegeneration, autism spectrum disorder, nonalcoholic fatty liver disease (NAFLD), fibrosis and cardiovascular disorders.
Cancer Focus Fund LP is investing US$5 million in funding to support ISA Pharmaceuticals BV's ISA-103 in a first-in-human study for the treatment of uveal melanoma.
Multiple myeloma (MM) represents about 10% of all blood cancers, remaining an incurable disease with a 5-year overall survival rate of 56%. B-cell maturation antigen (BCMA) is a receptor in the cell surface that is highly expressed in malignant plasma cells, and in normal cells, that promotes cell proliferation and survival by binding to APRIL and BAFF ligands.
CSPC Pharmaceutical Group Ltd. has received clearance from China's National Medical Products Administration (NMPA) to conduct clinical trials in China of the highly selective novel protein arginine methyltransferase 5 (PRMT5) inhibitor SYH-2045 for the treatment of advanced malignant tumors.
RSS
